Post by Algaurizin

The global launch playbook for innovative therapies is changing, and patient access is changing with it. For decades, pharmaceutical companies followed a predictable launch sequence: US → Europe → Japan → Rest of World. Today, that model is being rewritten. In the latest issue of TheAlgau | Pipeline to Market, we explore how International Reference Pricing (IRP), manufacturing constraints, and regional partnership strategies are reshaping when and where patients gain access to breakthrough therapies. Key insights from Issue #42: 🔹 54% of pharmaceutical companies now prioritize launching in high-price markets first to mitigate IRP pressures (up from 38% before major pricing reforms). 🔹 Patients in some regions may experience 12–18 month delays in access to innovative therapies due to launch sequencing strategies. 🔹 Limited biologics manufacturing capacity is influencing supply allocation decisions, even after regulatory approval. 🔹 Regional licensing and commercialization partnerships are emerging as critical tools for improving market access. For healthcare professionals, understanding these dynamics is becoming increasingly important for: ✅ Managing patient expectations ✅ Navigating treatment access challenges ✅ Planning bridge therapy strategies ✅ Collaborating effectively with pharmacy and payer stakeholders As innovation accelerates, ensuring equitable and timely patient access requires greater awareness of the commercial realities shaping global healthcare delivery. How have launch sequencing decisions or supply constraints affected access to therapies in your practice or market? Have these factors influenced your approach to patient management? I’d be interested to hear your perspectives and experiences. Read the full newsletter here: link in the comments #Healthcare #Pharma #MarketAccess